Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00854373 · ClinicalTrials.gov registry record · Phase 4
Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial
A Phase 4 study of Infertility, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 232
- Enrollment target
- 1
- Study location
NCT00854373: Completed Phase 4 study of Infertility, sponsored by University of California, San Francisco.
NCT00854373 is a Phase 4 study of Infertility that has completed, run by University of California, San Francisco. The registered enrollment target is 232 participants, below the 7,586-participant average among 74 other Infertility trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00854373, a Phase 4 study of Infertility, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 232 participants
- Enrollment target
- 1
- Study location
Study Summary
Marcelle Cedars, M.D., Victor Fujimoto, M.D., Mitch Rosen, M.D., Heather Huddleston, M.D., Paolo Rinaudo, M.D., Anthony Dobson, M.D., and Shehua Shen, M.D. from the UCSF Department of Obstetrics and Gynecology and Reproductive Sciences are conducting a study to learn about ovarian stimulation and oocyte maturation to improve fertilization, embryo quality, implantation and clinical pregnancy rates in patients undergoing in vitro fertilization (IVF). Two hormones, follicle stimulating hormone and human chorionic gonadotropin (FSH/hCG) will be compared to the standard one hormone, hCG, for the ovulation trigger. Over the past two decades, the success rate of assisted reproductive technology (ART) has dramatically increased. This increase has largely been attributed to improvements in the laboratory conditions and improvements in ovarian stimulation protocols (those medications used to increase the number of eggs maturing each cycle). Less work has been done on different ways to cause the final maturation of the eggs and the release of the egg from the ovary. The investigators propose to change the final injection prior to the egg retrieval (the ovulation trigger) so that it looks more like what happens in a normal menstrual cycle, where two hormones (both luteinizing hormone (LH) and FSH) increase. The investigators want to find out if this will improve egg quality and increase chances for pregnancy.
Primary Outcome
Number of normally fertilized oocytes (2PNs) divided by the total number of oocytes collected (i.e., not just the number of inseminated metaphase II state (MII) oocytes). This accounted for the possibility of both an enhanced oocyte maturation and improved fertilization of the mature oocytes. This also permitted inclusion of both IVF and intracytoplasmic sperm injection (ICSI) cycles in a way that allowed for evaluation of collective fertilization rates (i.e., typically, the denominator in IVF i
Conditions Studied
Interventions
- DRUG Bravelle(follicle stimulating hormone)
- OTHER Saline ( placebo)
Study Locations (1)
California
- UCSF- Mission Bay - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2007-06-01 |
| Est. Completion | 2010-04-20 |
| Phase | Phase 4 |
What the finished NCT00854373 record still lists
NCT00854373 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, below the 7,586-participant average among 74 other Infertility trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Infertility appearing as the primary indexed condition, and to 2 interventions - of which Bravelle(follicle stimulating hormone) is the first listed.
NCT00854373 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00854373 about?
NCT00854373 is a clinical study titled "Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial". Marcelle Cedars, M.D., Victor Fujimoto, M.D., Mitch Rosen, M.D., Heather Huddleston, M.D., Paolo Rinaudo, M.D., Anthony Dobson, M.D., and Shehua Shen, M.D. from the UCSF Department of Obstetrics and Gynecology and Reproductive Sciences are conducting a study to learn about ovarian stimulation and oo...
What is the current status of trial NCT00854373?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 232 participants. The study started on 2007-06-01. Estimated completion is 2010-04-20.
What conditions does trial NCT00854373 study?
This clinical trial studies the following conditions: Infertility.
What interventions are being tested in trial NCT00854373?
The interventions under investigation include: Bravelle(follicle stimulating hormone) (DRUG), Saline ( placebo) (OTHER).
Who is sponsoring clinical trial NCT00854373?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00854373 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infertility
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00854373's enrollment target sits among peer trials
232 40th of 74 higher than 35 of 74 other Infertility trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Infertility trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GnRH for Luteal Support in IVF/ICSI/FET Cycles
RECRUITING · Phase 4
-
Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation
ACTIVE NOT RECRUITING · Phase 4
-
Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
COMPLETED · Phase 4
-
Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer
COMPLETED · Phase 4
-
Menopur Mixed Protocol
COMPLETED · Phase 4
-
Gamete Treatment to Correct Fertilization Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI